0001104659-21-001637.txt : 20210106
0001104659-21-001637.hdr.sgml : 20210106
20210106184814
ACCESSION NUMBER: 0001104659-21-001637
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210104
FILED AS OF DATE: 20210106
DATE AS OF CHANGE: 20210106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Young Jonathan
CENTRAL INDEX KEY: 0001779805
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 21512260
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
tm211943-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-01-04
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001779805
Young Jonathan
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Operating Officer
Common Stock
2021-01-04
4
S
0
2960
25.27
D
181885
D
Common Stock
2021-01-04
4
S
0
100
26.00
D
181785
D
Common Stock
20000
I
By EA Irrevocable Trust
Common Stock
20000
I
By CM Irrevocable Trust
Common Stock
20000
I
By JL Irrevocable Trust
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.92 to $25.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Jonathan Young
2021-01-06